FTSE MIB
30.403,90 +282,13 (+0,94%) Dow Jones
36.247,87 +130,49 (+0,36%) Nasdaq
14.403,97 +63,98 (+0,45%) Nikkei 225
32.307,86 -550,45 (-1,68%) Petrolio
71,26 +1,92 (+2,77%) Bitcoin EUR
40.825,98 -279,59 (-0,68%)
AMGN Jan 2024 290.000 call
| Chiusura precedente | 1,8300 |
| Aperto | 1,4900 |
| Denaro | 1,1700 |
| Lettera | 1,3900 |
| Prezzo d'esercizio | 290,00 |
| Scadenza | 2024-01-19 |
| Min-Max giorno | 1,3400 - 1,5900 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 2,09k |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireAmgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan’s proprietary target discovery
